BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Europabio - ECPv6.15.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Europabio
X-ORIGINAL-URL:https://www.europabio.org
X-WR-CALDESC:Events for Europabio
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Brussels
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20201025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210712T090000
DTEND;TZID=Europe/Brussels:20210713T170000
DTSTAMP:20260527T145125
CREATED:20210623T145655Z
LAST-MODIFIED:20210623T150119Z
UID:2771-1626080400-1626195600@www.europabio.org
SUMMARY:EU Matchmaking Event on COVID-19 Therapeutics
DESCRIPTION:Building on the experience of the EU Task Force for Industrial Scale-up of COVID-19 vaccines\, the European Commission will facilitate cooperation between actors in the supply chain to ensure that available therapeutics are produced in sufficient quantity as soon as possible. In the context of a surge in demand\, it remains crucial to ensure the speedy production of current and new therapeutics against COVID-19. To support the industry\, the Commission organises the pan-EU matchmaking events for all supply chain actors\, so that they find solutions for the bottlenecks encountered. \n\n\n\nMedicines for COVID-19 are still in the development phase. Therefore\, the objective of the event is to help accelerate the development of new and repurposed medicines for COVID-19 therapeutics\, i.e. medicines specifically developed for an indication in treatment of COVID-19\, at all stages of COVID-19 disease and mobilise the EU pharma manufacturing capacity for their potential production. \n\n\n\nThe target group is the entire EU COVID-19 therapeutics value chain starting with researchers and developers\, through manufacturing companies and representatives of the hospitals\, who apply such therapeutics to their patients. The providers of ancillary functions such as clinical trials services\, accessories suppliers (e.g. vials\, syringes\, tubes etc.)\, funding providers and public procurers will also be targeted to take part in the event. \n\n\n\nThe event will take place virtually on 12th and 13th July 2021. 12th July will start with a half-day seminar setting the scene with a welcome by Commissioner Breton and Commissioner Kyriakides. \n\n\n\n\n\n\n\nHow to apply? \n\n\n\nIn order to apply to the event\, European companies must comply with the requirements stated in the event’s Call for Expression of Interest. Register until June 25.
URL:https://www.europabio.org/event/eu-matchmaking-event-on-covid-19-therapeutics/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2021/06/European-Matchmaking-event-e1624460170563.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210630T121500
DTEND;TZID=Europe/Brussels:20210630T134500
DTSTAMP:20260527T145125
CREATED:20210609T145626Z
LAST-MODIFIED:20210611T110808Z
UID:2648-1625055300-1625060700@www.europabio.org
SUMMARY:Changing Global Ambitions for Biotechnology Innovation: Implications and Drivers for Europe
DESCRIPTION: \nEuropaBio hosts a member-only discussion session looking at ambitions for innovation and business in China\, and how this impacts both the EU and US. We are delighted to welcome McKinsey’s China office to the meeting\, where they will present an inside look at changing Chinese ambitions for industrial growth from innovation.\n \nMember discussion then focuses on how Europe can deliver its own ambitions in a world where changes beyond its borders will influence success\, and how it needs to develop a strong and realistic economic vision for technology from companies and governments.\n \nEuropaBio looks forward to an interesting cross-sector debate amongst Members on the long-term future of Europe as a global competitor and economic performer within the technology space\, within profound economic changes world-wide.\n \nAll members are eligible to attend and should contact EuropaBio (m.cilia@europabio.org) if they have not yet received an invitation.
URL:https://www.europabio.org/event/changing-global-ambitions-for-biotechnology-innovation-implications-and-drivers-for-europ/
CATEGORIES:EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/06/Event-Banners-25.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210610T120000
DTEND;TZID=Europe/Brussels:20210618T120000
DTSTAMP:20260527T145125
CREATED:20210408T080837Z
LAST-MODIFIED:20210408T081528Z
UID:1994-1623326400-1624017600@www.europabio.org
SUMMARY:BIO Digital 2021 - Rise
DESCRIPTION:Accelerating a BIO-Revolution through global partnerships\, collaboration\, and thought leadership. \n\n\n\n\n\n\n\n\n\nJoin The World’s Largest Global Biotech Partnering Experience \n\n\n\nFrom the 10th to June 18th takes place the world’s largest biotechnology partnering event BIO digital 2021\, promoted by the Biotechnology Innovation Organization (BIO). \n\n\n\nThis international convention represents a unique opportunity for companies and institutions related to biotechnology to obtain information of high scientific and financial value\, close strategic alliances\, obtain financing for their projects and get new clients. The event offers an extensive program that includes academic activities\, networking events\, company presentations\, an exhibition area (considered the largest in the world of those specialized in this sector)\, seminars and conferences on new trends in biotechnology and innovations\, among others. \n\n\n\n \n\n\n\n\nRegister here
URL:https://www.europabio.org/event/bio-digital-2021-rise/
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/04/Event-Banners-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210603T140000
DTEND;TZID=Europe/Brussels:20210603T150000
DTSTAMP:20260527T145125
CREATED:20210315T132511Z
LAST-MODIFIED:20210602T083815Z
UID:1616-1622728800-1622732400@www.europabio.org
SUMMARY:EU Healthcare Biotech Policy Priorities for SMEs
DESCRIPTION:Join the EuropaBio Healthcare Biotechnology Team for a dive into EU policies that impact your current operations and will shape your future strategies. With the ongoing revision of the basic pharmaceutical legislation and of regulations for medicines for rare and paediatric diseases\, SMEs should be planning how they build and grow their businesses\, whether within the EU or outside. \n\n\n\nAbout the EuropaBio SME Platform \n\n\n\nThe SME platform is a community of SMEs across all sectors in Europe\, supported through regular online meetings around EU-level topics that impact commercial biotechnology and represented to EU stakeholders. \n\n\n\n  \n\n\n\n\nREGISTER HERE\n\n\n\n\n\n\n\n\n 
URL:https://www.europabio.org/event/eu-healthcare-biotech-policy-priorities-for-smes/
CATEGORIES:EuropaBio,Healthcare Biotech,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/03/Event-Banners-9-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210602T090000
DTEND;TZID=Europe/Brussels:20210603T170000
DTSTAMP:20260527T145125
CREATED:20210209T180700Z
LAST-MODIFIED:20210308T093844Z
UID:1303-1622624400-1622739600@www.europabio.org
SUMMARY:Global Access to Innovations in Healthtech (GAINH) Summit
DESCRIPTION:The Global Access to Innovations in Healthtech Summit is a biennial EXCITE International summit\, a Canada based not-for-profit initiative. The 2021 edition will be organized in collaboration with HI-NL\, a Dutch organization. \n\n\n\nGAINH 2021 will be the first edition taking place in Europe. \n\n\n\nThe biennial summit has a unique approach that engages industry\, payers\, health systems\, expert end-users and patients across the full pathway\, from innovation to adoption\, bringing these technologies to market with greater certainty and at a lower cost. \n\n\n\nTogether with HI-NL\, EXCITE International will bring the European and American markets together to accelerate the pathway from innovation to adoption. \n\n\n\nAbout the organizers \n\n\n\nEXCITE International and Health Innovation Netherlands (HI-NL) closely collaborate to work towards the common goal of helping innovative medical technologies become accessible to patients\, civilians and care providers through a more timely and streamlined process of evaluation\, market access\, implementation\, adoption and reimbursement. \n\n\n\nThis is achieved by ensuring that all relevant stakeholders who are involved in the life cycle of medical technology\, are as early as possible involved in this process. Both organizations are focused on changing the landscape of the medical technology space and believe that innovative ideas that are transformed into medical technological innovations\, have the power to shift the patient\, civilian and care provider experiences. \n\n\n\nThrough their collaboration\, EXCITE International and HI-NL are creating the bridge between the North American and European medical technology sectors\, where stakeholders and their experiences can easily be exchanged. \n\n\n\n\n\n\n\n(GAINH 2021 is organized by Hyphen Projects\, a specialized project office that initiates\, develops and organizes career fairs\, networking events\, websites and other formats for the Life Sciences and related sectors).
URL:https://www.europabio.org/event/global-access-to-innovations-in-healthtech-gainh-summit/
LOCATION:VIRTUAL\, Veerstraat 37\, Hilversum\, 1211 HJ\, Netherlands
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-GAINH.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210527T130000
DTEND;TZID=Europe/Brussels:20210527T143000
DTSTAMP:20260527T145125
CREATED:20210511T134921Z
LAST-MODIFIED:20210528T100244Z
UID:2445-1622120400-1622125800@www.europabio.org
SUMMARY:EFIB 2021 Kick-Off Webinar - How to accelerate biotech innovation for a sustainable future
DESCRIPTION:Get ready for EFIB 2021 by joining our launch webinar “How to accelerate biotech innovation for a sustainable future”. \n\n\n\n EuropaBio is pleased to announce this kick-off webinar\, co-hosted by DSM and Planet B.io\, both located at the Biotech Campus Delft. The webinar will feature industry\, start-up\, and financing perspectives on the European biotechnology innovation ecosystem.  \n\n\n\nIt will provide insights on recent developments in the field\, discuss cooperation in the field and have an outlook on what to expect at EFIB 2021 in Vienna this year.  \n\n\n\nSpeakers:\n\n\n\n– Claire Skentelbery – General Director\, EuropaBio– Cindy Gerhardt – Managing Director\, Planet-B.io at the Biotech Campus Delft– Rob van der Meij – Partner\, Capricorn Partners– Amadeus Driando Ahnan-Winarno – Co-Founder & Head of Technology\, Better Nature \nYou can watch the video recording here\, or download the speakers’ presentations here. \n\n\n\n\n\n\n\n\n\n\nREGISTER HERE\n\n\n\n\n\n\n\n\n\n\n 
URL:https://www.europabio.org/event/efib-2021-kick-off-webinar-how-to-accelerate-biotech-innovation-for-a-sustainable-future/
CATEGORIES:EuropaBio,Industrial Biotech
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2021/05/Event-Banners-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210520T140000
DTEND;TZID=Europe/Brussels:20210520T150000
DTSTAMP:20260527T145125
CREATED:20210421T071455Z
LAST-MODIFIED:20210517T090546Z
UID:2157-1621519200-1621522800@www.europabio.org
SUMMARY:Then and Now – Delivering a Successful Therapeutic to Patients
DESCRIPTION:In today’s whirlwind of diagnostics\, vaccines and therapeutics\, we take a step back and look at how the world of development and manufacturing of biologics has evolved over the last 25 years\, bringing together EuropaBio Members and 25th Anniversary Sponsor\, Catalent.We look back at changing experience from the last quarter of a century in the pathway to patients\, plus how the latest advanced technologies translate into effective pre-clinical and clinical development and manufacturing. Hear expert presentations from EuropaBio Members and Catalent Biologics\, before a detailed Q&A session with the audience on all aspects of developing a successful biologic in 2021. \n\n\n\nAspects to be discussed include: \n\n\n\nWhat trends are driving growth in the pharma industry\, and how are next generation therapies addressing previously unmet needs?As advanced technologies travel through the pipeline\, how are pharma companies\, CDMOs and other partners able meet their complex and novel requirements?In a global world\, how do you embrace and integrate skills and capacity from multiple sites\, often in different continents?As complex\, advanced medicines become reality\, how do you work with regulators from the earliest stages of pre-clinical development to enable a smooth pathway to clinic and market?\n\n\n\nFEATURED SPEAKERBehzad Mahdavi\, Ph.D.​Vice President of Open Innovation\, Biologics\, Cell and Gene Therapy \n\n\n\nMartine Lewi\,​Scientific Director\, Janssen R&D/Clinical Innovation \n\n\n\n \n\n\n\nWith over 20 years’ experience in developing and implementing impactful growth strategies in the biopharmaceutical industries\, Dr. Mahdavi joined Catalent in 2020 after a 13-year career at Lonza\, where he held the role of Vice President Strategic Innovation & Alliances\, and various board-level positions at other innovative companies. Prior to joining Lonza\, he was Chief Executive Officer of SAM Electron Technologies\, a venture capital-backed company in the life sciences field. He holds a doctorate in chemistry from the University of Sherbrooke\, Canada\, and also has a master’s in business administration from the University of Quebec in Montreal. \n\n\n\nJoin this webinar co-organised by Catalent and EuropaBio in the framework of EuropaBio 25th Anniversary and take part to the celebrations!  \n\n\n\n \n\n\n\n \n\n\n\n\nREGISTER HERE
URL:https://www.europabio.org/event/then-and-now-delivering-a-successful-therapeutic-to-patients/
CATEGORIES:EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/04/Catalent-Webinar.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210518T103000
DTEND;TZID=Europe/Brussels:20210518T143000
DTSTAMP:20260527T145125
CREATED:20210324T082247Z
LAST-MODIFIED:20210427T094258Z
UID:1606-1621333800-1621348200@www.europabio.org
SUMMARY:EuropaBio Patient BioForum: Advancing patient access to innovative treatments
DESCRIPTION:2021 is set to be another landmark year in the area of health. It is hoped to not only relieve the burden of the COVID-19 pandemic on EU patients and healthcare systems\, but also let the health community advance the great number of other priorities there are. In the EU\, 2021 is set to give a start to the implementation of the European Health Union and the related objectives of the new EU Pharmaceutical Strategy. Among these\, the EU health community is looking to improve patients’ access to therapies for challenging and rare conditions. \n\n\n\nThis meeting of EuropaBio’s Patient BioForum will discuss avenues for enhancing the access of EU patients to novel biotechnology-derived treatments in two sessions: \n\n\n\nMorning session – 10:30-12:00 CET\n\n\n\nPharmaceutical Strategy implementation for continued innovation and delivery in the area of rare and paediatric diseases. \n\n\n\nThe European Commission is discussing on the calibration of incentives for investing in the development of medicines for rare and paediatric diseases both with Member States and stakeholders. We invite the BioForum members to exchange proposals for informing this important debate on several key points\, such as criteria for defining unmet need and incentivising innovation in such areas\, etc. \n\n\n\nAfternoon session – 13:00-14:30 CET\n\n\n\nImproving patient access across borders \n\n\n\nThe EU Directive on cross-border healthcare is an important instrument to ensure patient access to the best available care. The Directive is particularly relevant for advanced therapies and medicines for rare diseases. Well-functioning EU cross-border healthcare legislation can ensure patients have access to specialised treatments and novel therapies when these are not available in their home country. \n\n\n\nThe exchange between guest speakers and BioForum members is aimed to result in the post-meeting release of policy recommendations for how patient access can be advanced in the EU in the context of its new Pharmaceutical Strategy. \n\n\n\nWe very much look forward to your active participation on 18 May 2021.  \n\n\n\n \n\n\n\nVIRTUAL EVENT
URL:https://www.europabio.org/event/europabio-patient-bioforum-advancing-patient-access-to-innovative-treatments/
CATEGORIES:EuropaBio,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/03/Event-Banners-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210518T090000
DTEND;TZID=Europe/Brussels:20210520T170000
DTSTAMP:20260527T145125
CREATED:20210210T205019Z
LAST-MODIFIED:20210212T162627Z
UID:1353-1621328400-1621530000@www.europabio.org
SUMMARY:Renewable Materials Conference
DESCRIPTION:Featuring a unique concept to present all sustainable and renewable material solutions at one event: bio-based\, CO2-based and recycled. This time\, the conference will be held as hybrid event. 300 to 400 participants are expected. \n\n\n\nThere is a growing market demand for advanced and ready-to-use sustainable material solutions with a low carbon footprint – and fossil-free. As a response to this challenge\, nova-Institute has decided to unite all relevant industries in the new Renewable Materials Conference (RMC). Over three days\, participants get a complete overview of the latest renewable material solutions from a wide range of sustainable raw materials and technologies. \n\n\n\nThe first day will be focusing on building blocks and chemicals\, the second on polymers and plastics and the third on plastic and composite materials. Or in other words: All material solutions based on renewable carbon – avoiding the use of additional fossil carbon. \n\n\n\nThe Renewable Materials Conference is the follow-up event to the “13th International Conference on Bio-based Materials”\, which builds on a successful history of previous conferences: In 2019\, more than 270 participants attended and 30 exhibitors were present. It was the second largest event on bio-based materials in Europe and continues within this new concept. The conference also integrates topics from the “Biocomposites Conference Cologne” and extends the conference with presentations on chemicals and polymers from CO2 use (CCU) as well as new solutions from the field of recycling\, so that the entire spectrum of renewable materials is covered. \n\n\n\nnova-Institute’s renewable carbon approach aims to initiate the end of the fossil age of chemicals and plastics and builds the foundation for the RMC. Renewable chemicals\, plastics\, composites\, fibres and other products can be produced either from biomass\, directly via CO2 utilisation\, or recycling. Naturally\, this includes the established areas of bio-based polymers and biocomposites. \n\n\n\nThe conference will help shape the sustainable future of chemicals and materials and will provide new advantages and synergies by establishing a meeting point for numerous cross-sectoral networking opportunities.
URL:https://www.europabio.org/event/renewable-materials-conference/
LOCATION:NovaInstitute\, Chemiepark Knapsack Industriestraße 300\, Huerth\, 50354\, Germany
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-Renewable-Materials.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210511T120000
DTEND;TZID=Europe/Brussels:20210511T130000
DTSTAMP:20260527T145125
CREATED:20210312T082225Z
LAST-MODIFIED:20210506T121206Z
UID:1571-1620734400-1620738000@www.europabio.org
SUMMARY:Taking health up a gear: value of advanced therapies
DESCRIPTION:Advanced therapies have ground-breaking therapeutic potential\, particularly in disease areas where there is an unmet medical need and available therapeutic options are absent or inadequate. These therapies can bring the possibility of a cure to life-threatening conditions with a one-off treatment\, thereby changing the paradigm of providing health and care to patients suffering serious\, rare or complex diseases. \n\n\n\nA breakthrough innovator in the area of rare diseases will explain the cutting-edge science behind gene therapies\, why they are considered so transformative\, and what promise they hold to addressing unmet patient needs. \n\n\n\nA leading developer of the most innovative cancer treatments – CAR-T cell-based therapies will explain the changing paradigm of providing health for cancer patients and how innovation will help achieve the objectives of Europe’s Beating Cancer Plan. \n\n\n\nThe webinar will also engage policy makers reflecting live on how EU policies can truly harness the ground-breaking potential of advanced therapies. \n\n\n\nSpeakers \n\n\n\nSara Cerdas MEP\, BECA \n\n\n\nDick Sundh\, Head of ACE (Australia\, Canada & Europe) at Kite Pharma\, a Gilead Company  \n\n\n\nDirk Vander Mijnsbrugge\, Vice President Medical Affairs Lead Rare Diseases International Developed Markets at Pfizer \n\n\n\nSimone Boselli\, Public Affairs Director at EURORDIS  \n\n\n\n \n\n\n\nAbout EuropaBio Advanced Therapies Series: \n\n\n\nThe EuropaBio Advanced Therapies series of events\, interviews\, and publications will engage policymakers\, regulators\, patients and their representatives\, developers\, and all relevant stakeholders to discuss how innovation in gene- and cell-based medicine can bring a transformative value for patients. \n\n\n\nThroughout 2021\, we invite you to join us on a journey of exploring the tremendous potential of advanced therapies by discussing the new treatment paradigms\, the future of research and development in this fast-moving space of bio-science\, as well as debating recommendations for improving the access of patients to these ground-breaking treatments and supporting advanced manufacturing\, to name a few. \n\n\n\nVIRTUAL EVENT \n\n\n\n\nREGISTER HERE
URL:https://www.europabio.org/event/taking-health-medicine-up-a-gear-value-of-advanced-therapies/
CATEGORIES:EuropaBio,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/03/Event-Banners-10.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210510T150000
DTEND;TZID=Europe/Brussels:20210510T180000
DTSTAMP:20260527T145125
CREATED:20210316T153010Z
LAST-MODIFIED:20210511T074409Z
UID:1593-1620658800-1620669600@www.europabio.org
SUMMARY:Building on biotechnology: From vaccines to economic growth for Europe
DESCRIPTION:EuropaBio National Associations Council\n\n\n\nSummit 2021 – Portugal \n\n\n\n \n\n\n\n\n\n\n\n\n\nEuropaBio’s National Associations Council (NAC) is a platform that brings together all EuropaBio’s National Associations and helps to ensure coordination of EuropaBio actions throughout Europe. The NAC represents biotechnology priorities across Europe’s Member and partner countries\, working together to build long term economic and societal benefit from biotechnology across sectors. \n\n\n\nIn 2021\, the NAC is proud to host its first Summit focussed on priorities for commercial biotechnology development\, delivering the Industrial Strategy within national and European ecosystems. \n\n\n\nThe NAC summit on May 10 will address how we learn from the COVID-19 response\, to enable full societal and economic benefit from biotechnology in the future across sectors. Rapid technology development pathways\, including partnering\, investment and approvals\, created in response to the pandemic have created new\, faster routes to market. Although this was a unique scale and speed for vaccine development\, it shows that biotech can perform quickly and strongly to address unmet issues in healthcare and sustainable development\, creating a solution and also supporting economic recovery across Europe. \n\n\n\nThe EuropaBio NAC Summit is held during the Portuguese Presidency of the Council of EU and organized in collaboration with P-BIO. The outcomes from the Summit will include a EuropaBio NAC Position on building economic pathways from biotech post-Covid with the role of aligned and ambitious national policies and actions. \n\n\n\n \n\n\n\nAgenda\n\n\n\n15:00: Welcome – Claire Skentelbery\, Director General\, EuropaBio \n\n\n\n15:05: Opening remarks – Manuel Heitor\, Minister of Science\, Technology and Higher Education\, Portugal \n\n\n\n15:15: A European ambition in a competitive global landscape. \n\n\n\nWhere biotech and economic ambitions sit within European and global strategies – Claire Skentelbery\, Director General\, EuropaBio \n\n\n\n \n\n\n\n15:30: Session 1 – A new biotechnology ecosystem in Europe \n\n\n\n\nCompanies active in the current response to Covid-19 share how they have built vital collaborations across the biotech-pharma spectrum to deliver breakthrough vaccine technologies to patients at unprecedented speed\, plus how they envision future potential. \n\n\n\n15:30: Economic development driven by Biotech – the Portugal perspective: David Malta\, Founding CEO\, LiMM Therapeutics \n\n\n\n15:45: Developing bio-manufacturing partnerships – Elke Grooten\, Head of EU Relations\, Novartis \n\n\n\n16:00: Pharma-SME collaboration: from innovation to patient\, a global journey – Sinan Atlig\, Regional President IDM\, Vaccines Pfizer \n\n\n\n16:15: Break \n\n\n\n\n16:30: Session 2 – Looking to the future – speed and strength from biotech \n\n\n\nSMEs driving next generation biotechnology present the pathway and challenges to success and highlight what Europe needs to achieve.  EuropaBio National Associations will then discuss the critical framework needed to build further from national and European ecosystem advances from Covid\, accelerating biotech contribution to Europe’s economic development. \n\n\n\nSME drivers \n\n\n\n16:30: The future of vaccines – Bruno Santos\, Co-Founder and CEO\, IMMUNETHEP \n\n\n\n16:40: Reaching all patients for immunity – Kim Kjøller\, CEO\, UNION Therapeutics \n\n\n\nBuilding European strengths \n\n\n\n16:50: Discussion Panel – Associations from across Europe plus audience contributions \n\n\n\nModerator: Claire Skentelbery \n\n\n\nPanellists:  \n\n\n\n– Agne Vaitkeviciene\, Executive Director\, Lithuanian Biotechnology Association \n\n\n\n– Chloe Evans\, Market Research Manager & International Relations\, France Biotech \n\n\n\n– Simão Soares\, President\, P-BIO \n\n\n\n– Hanne Mette Dyrlie Kristensen\, CEO\, The Life Science Cluster (Norway) \n\n\n\n18:00: Summary and Close \n\n\n\nVIRTUAL EVENT \n\n\n\n\nREGISTER HERE\n\n\n\n\nWho should attend? \n\n\n\nThe EuropaBio NAC Summit is open and free of charge.  You should attend if you are active within the development of biotechnology ecosystems at national or European levels\, either as a technology stakeholder (academic or industrial) or a facilitator of technology maturation to market and patients (associations\, tech transfer\, investors\, policy makers…). The event will have a strong discussion element and all participants can be actively involved. The event will also develop preparatory statements for delegate feedback plus post-event discussion on the planned NAC Position. \n\n\n\nDownload below the speakers’ presentations: \n\n\n\nEuropaBio-NAC-Summit-10-May-2021-Slides-FINAL-PDFDownload
URL:https://www.europabio.org/event/building-on-biotechnology-from-vaccines-to-economic-growth-for-europe/
CATEGORIES:EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/03/Event-Banners-3.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210428T090000
DTEND;TZID=Europe/Brussels:20210430T170000
DTSTAMP:20260527T145125
CREATED:20210304T110651Z
LAST-MODIFIED:20210429T092459Z
UID:1514-1619600400-1619802000@www.europabio.org
SUMMARY:German Corona Showcase
DESCRIPTION:A considerable part of the global activities for the development and production of diagnostics\, vaccines and drugs against Covid-19 takes place at biotech sites in German-speaking countries. \n\n\n\nThe e-Vent will… \n\n\n\nGive the opportunity to discuss funding\, procurement and governmental supportGive the opportunity to exchange an discuss experiences made with corona researchProvide industry insights and expert views for press representatives and government employee\n\n\n\n\n\n\nVIRTUAL EVENT
URL:https://www.europabio.org/event/german-corona-showcase/
CATEGORIES:All
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2021/03/Corona-Showcase.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210422T140000
DTEND;TZID=Europe/Brussels:20210422T150000
DTSTAMP:20260527T145125
CREATED:20210315T132400Z
LAST-MODIFIED:20210409T131755Z
UID:1588-1619100000-1619103600@www.europabio.org
SUMMARY:EU Industrial Biotech Policy Priorities for SMEs
DESCRIPTION:Join the EuropaBio Industrial Biotechnology Team for a dive into EU policies that impact your current operations and will shape your future strategies.  With the Green Deal\, Industrial Strategy\, Circular Economy and many more\, SMEs can take advantage of changes and opportunities to plan and grow their business. \n\n\n\nAbout the EuropaBio SME Platform \n\n\n\nThe SME platform is a community of SMEs across all sectors in Europe\, supported through regular online meetings around EU-level topics that impact commercial biotechnology and represented to EU stakeholders. \n\n\n\n \n\n\n\n\nREGISTER HERE
URL:https://www.europabio.org/event/eu-industrial-biotech-policy-priorities-for-smes/
CATEGORIES:EuropaBio,Industrial Biotech,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/03/SME-April-22-Event-Banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210422T090000
DTEND;TZID=Europe/Brussels:20210422T101500
DTSTAMP:20260527T145125
CREATED:20210408T075359Z
LAST-MODIFIED:20210412T140755Z
UID:1982-1619082000-1619086500@www.europabio.org
SUMMARY:Think\, Act\, EUnite: A post-COVID-19 paradigm shift in European healthcare
DESCRIPTION:A PUBLIC webinar sponsored by the Novartis EUnite4Health Ecosystem Team \n\n\n\nFor citizens\, industry\, and institutions\, COVID-19 was a stress test that revealed faults in our current health ecosystem. From a less-than-optimal regulatory review and approval processes which limit patient access\, to an industrial manufacturing network that could be improved\, and an R&D ecosystem that is not achieving its full potential\, we have collectively witnessed a health ecosystem ready for evolution. \n\n\n\nAs Europe looks to adopt the “lessons learned” from this crisis\, now is an opportune moment to create change\, discuss opportunities\, and build a future-ready health policy. \n\n\n\nOn behalf of EuropaBio\, JA Europe\, and Novartis\, we are pleased to share a save the date for our Think\, Act\, EUnite: A post-COVID-19 paradigm shift in European healthcare\, PUBLIC webinar to discuss what the future of healthcare in Europe could look like. \n\n\n\nConfirmed speakers include: \n\n\n\nTomislav Sokol\, Member of the European Parliament (EPP\, Croatia) \n\n\n\nSeán Kelly\, Member of the European Parliament (EPP\, Ireland) \n\n\n\nIrene Norstedt\, Director\, People\, DG Research and Innovation (RTD)\, European Commission \n\n\n\nMary Harney\, Former Irish Minister of Health \n\n\n\nBettina Ryll\, Member of the European Commission’s Cancer Mission Board\, Physician and Founder of Myeloma Patient Network Europe \n\n\n\nClaire Skentelbery\, Director-General of EuropaBioKees Roks\, Head of Region Europe\, Novartis Oncology and Member of the European Commission’s Cancer Mission Assembly \n\n\n\nVirtual Event \n\n\n\n\nRegister here
URL:https://www.europabio.org/event/think-act-eunite-a-post-covid-19-paradigm-shift-in-european-healthcare/
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/04/Event-Banners-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210419T090000
DTEND;TZID=Europe/Brussels:20210421T170000
DTSTAMP:20260527T145125
CREATED:20210210T204608Z
LAST-MODIFIED:20210312T150614Z
UID:1347-1618822800-1619024400@www.europabio.org
SUMMARY:Nordic Life Science Days
DESCRIPTION:Nordic Life Science Days is the largest Nordic partnering conference dedicated to the life science industry. Since its inception in 2013\, the event has nurtured a community of people from the world of life science\, and created a unique place to do business. Most attendees express their delight in the informal atmosphere\, combined with an organised approach to meeting highly relevant people. Return visitors come back because they feel they belong to our growing community. \n\n\n\nWe hope to welcome you in Digital format too. We will create live and virtual spaces for meaningful encounters\, with one-on-one meetings being one of the main features of NLSDays. Additionally\, the high quality of topics and presenters provide insight into the most recent trends in science and business. \n\n\n\nNLSDays attracts leading decision makers from biotech\, pharma and medtech as well as finance\, research\, policy and regulatory authorities. \n\n\n\nVIRTUAL EVENT
URL:https://www.europabio.org/event/nordic-life-science-days/
LOCATION:SwedenBIO\, Wallingatan 24\, Stockholm\, 111 24\, Sweden
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-NLS.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210415T130000
DTEND;TZID=Europe/Brussels:20210415T143000
DTSTAMP:20260527T145125
CREATED:20210316T094808Z
LAST-MODIFIED:20210318T105028Z
UID:1575-1618491600-1618497000@www.europabio.org
SUMMARY:An EU Vision for Life Science and Biotechnology for a Healthy and Sustainable EU
DESCRIPTION:With the ambitious target to cut greenhouse gas emissions by 55% compared to 1990 levels by 2030 and the EU Green Deal\, the EU has set clear goals to transform the bloc´s economy making it more sustainable while supporting the EU recovery. \n\n\n\nLife sciences and biotechnology remain critical key-enabling technologies for the economy\, generating GDP of over €34.5 billion\, employing 223\,000 people directly in the EU and generating a trade surplus of €22 billion in 2018.  Moreover\, the CO2 mitigation potential of industrial biotech is estimated between 1-2.5 billion tonnes of CO2 equivalent per year by 2030. \n\n\n\nThe Danish life science and biotechnology contributed to the local economy with over €14 billion export of goods and employing around 48\,000 jobs in 2019. Given the importance of this sector for the Danish economy\, the government is working on a new political strategy for the life science sector to succeed the sector’s growth plan implemented in March 2018. \n\n\n\nThe current COVID-19 pandemic has highlighted the need to employ a holistic and strategic approach and exploit synergies among various EU policies\, such as in the areas of research and innovation\, industry and health. Furthermore\, it showed us that the speed at which technologies develop requires that legislation is constantly up-to-date and able to embrace new sustainable innovation. Investing in the transition to a new sustainable economy requires modernised legislation that can support the green transition in the Member States and support the advancement of the EU life science and biotechnology to ensure they continue their main purpose to support the European Union’s ambitious agenda for healthy people and healthy planet. \n\n\n\nVIRTUAL EVENT
URL:https://www.europabio.org/event/an-eu-vision-for-life-science-and-biotechnology-for-a-healthy-and-sustainable-eu/
CATEGORIES:EuropaBio,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/03/Event-Banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210415T090000
DTEND;TZID=Europe/Brussels:20210416T170000
DTSTAMP:20260527T145125
CREATED:20210210T204147Z
LAST-MODIFIED:20210312T150539Z
UID:1343-1618477200-1618592400@www.europabio.org
SUMMARY:Innovation for Health - Shaping the Future of Healthcare
DESCRIPTION:On 15-16 April 2021\, the 8th edition of Innovation for Health takes place as an online edition with hybrid aspect. Innovation for Health is the meeting place where over 900 bright minds from across Health and Life Sciences come together to shape the future of healthcare. The theme of this year’s conference is immunology\, a topic that\, because of the COVID-19 pandemic\, has never been more relevant. With our energizing programme\, we bring over 40 top-notch speakers to the stage\, display high impact innovations\, highlight best practices\, and demonstrate inspiring developments in healthcare. Inspiring\, interacting\, and networking are at the heart of the conference. Innovation for Health is the leading conference for key players in Health & Life Sciences. \n\n\n\nVIRTUAL EVENT
URL:https://www.europabio.org/event/innovation-for-health-shaping-the-future-of-healthcare/
LOCATION:VIRTUAL\, Hyphen Projects - Veerstraat 37\, Hilversum\, 1211 HJ\, Netherlands
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-Innovation-for-Health.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210407T140000
DTEND;TZID=Europe/Brussels:20210407T140000
DTSTAMP:20260527T145125
CREATED:20210308T093624Z
LAST-MODIFIED:20210308T093625Z
UID:1550-1617804000-1617804000@www.europabio.org
SUMMARY:All About RC(I) – Discussing the Renewable Carbon Strategy and Initiative
DESCRIPTION:Discuss the concept of renewable carbon and get answers to all your questions. Get to know the people and companies behind the Renewable Carbon Initiative and learn why your company should join. RCI members Cosun and UPM and nova-Institute will discuss and answer your questions. \n\n\n\nAbout the organizers \n\n\n\nThe Renewable Carbon Initiative (RCI) was initiated by nova-Institute after observing the struggles of the chemical and plastics industry facing the enormous challenges in meeting the climate goals set by the European Union and the sustainability expectations held by societies around the globe. It was clear that the industry has to go beyond using renewable energy. As decarbonisation is not an option for organic chemistry\, which is entirely based on the use of carbon\, an alternative strategy was needed. \n\n\n\n\n\n\n\n\n\nVIRTUAL EVENT
URL:https://www.europabio.org/event/all-about-rci-discussing-the-renewable-carbon-strategy-and-initiative-2/
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/03/Event-Banners.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210323T090000
DTEND;TZID=Europe/Brussels:20210324T170000
DTSTAMP:20260527T145125
CREATED:20210210T203214Z
LAST-MODIFIED:20210312T150444Z
UID:1337-1616490000-1616605200@www.europabio.org
SUMMARY:9th Conference on CO2-based Fuels and Chemicals
DESCRIPTION:The conference is one of the oldest and most established worldwide and has developed into a unique meeting place for the entire Carbon Capture & Utilisation (CCU) and Power-to-X industry and its customers. \n\n\n\nThe first day will focus on CO2-based transport and aviation fuels\, the second on CO2-based bulk and fine chemicals. CCU technologies are essential to meet the future demand for carbon from renewable sources. Take a look into the near future and exchange ideas with the leading pioneers. \n\n\n\nCCU is one essential pillar for the supply of renewable carbon besides biomass and recycling. The transition to direct CO2 utilisation as one alternative carbon source is needed to substitute fossil sources\, to fight climate change and to shift towards sustainable and climate-friendly production and consumption. For providing the full benefits of CCU technologies the use of renewable energy is indispensable. Especially the supply of green hydrogen is crucial for the production of CO2-based transportation and aviation fuels\, bulk and fine chemicals. \n\n\n\nA large number of European cross-sectoral projects for hydrogen production via large-scale electrolysers have been announced recently. The European Commission launched a 400 Billion hydrogen strategy for the full energy transition to renewable energies\, as well as for the further use of hydrogen in innovations and technologies such as the production of high-volume synthetic fuels and chemicals. \n\n\n\nMeanwhile\, 100 projects on CO2-based fuel and chemical production\, as well as efficient capture and utilisation technologies have been launched by several start-ups and established companies\, ranging from pilot over demonstration to commercial scale. Even more players show their interest in getting involved in CCU and are increasingly planning and implementing more plants on different scales for Power-to-X technologies\, low carbon fuels and a CO2-based chemistry. Great visions are becoming real business cases and innovations are starting to realise their potential! \n\n\n\nNew and leading players will showcase novel and improved applications based on the use of CO2 as feedstock. Main topics of the conference are green hydrogen production\, carbon capture technologies and carbon utilisation (Power-to-X): Transportation and aviation fuels\, building-blocks\, bulk and fine chemicals as well as advanced technologies for CO2 utilisation such as artificial photosynthesis.
URL:https://www.europabio.org/event/9th-conference-on-co2-based-fuels-and-chemicals/
LOCATION:NovaInstitute\, Chemiepark Knapsack Industriestraße 300\, Huerth\, 50354\, Germany
CATEGORIES:External,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-Cologne.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210322T090000
DTEND;TZID=Europe/Brussels:20210325T170000
DTSTAMP:20260527T145125
CREATED:20210210T202010Z
LAST-MODIFIED:20210212T162759Z
UID:1331-1616403600-1616691600@www.europabio.org
SUMMARY:BIO-Europe Spring 2021
DESCRIPTION:The “must-attend” event series has gone digital\, and continues to grow from strength to strength\, proving its importance and relevance to the life science sector. Building on the success and momentum created by BIO-Europe Digital 2020 this past October our upcoming BIO-Europe Spring Digital will deliver more licensing opportunities\, more partnering meetings\, and more hot-off-the-press content than ever.    \n\n\n\nHere’s what will be different for 2021:    \n\n\n\nPRE-RELEASED CONTENT. The digital event will open 5 weeks early with on-demand content (panels\, company presentations and company showcases) to complement your partnering preparations and maximize your digital experience. partneringONE ALL in ONE. Our gold standard partnering platform has been transformed for the virtual era! With ONE login\, you access the entire event. No need to switch back and forth between platforms. Search by company or therapeutic area to discover potential partners and relevant conference sessions and company presentations.ONE SCHEDULE. To satisfy a truly global audience made up of thousands of delegates from more than 55 countries\, we provide one schedule that accommodates ALL TIME ZONES.   SOCIAL NETWORKING OPPORTUNITIES. We understand the value of networking outside of one-to-one meetings. In order to fill that void\, we created the “W
URL:https://www.europabio.org/event/1331/
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-Bio-Europe-Spring.png
ORGANIZER;CN="EBD by InformaConnect":MAILTO:EBDcustomerservice@ebdgroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210318T160000
DTEND;TZID=Europe/Brussels:20210318T170000
DTSTAMP:20260527T145125
CREATED:20210128T145930Z
LAST-MODIFIED:20210212T162821Z
UID:957-1616083200-1616086800@www.europabio.org
SUMMARY:KeyGene’s two-part webinar on PanGenomes: needs\, value and applications (part 2)
DESCRIPTION:This two-part webinar on PanGenomes\, which Keygene organizes together with an academic partner and Allen Sessions from BASF\, will explain what one needs to construct PanGenomes and highlight their value in breeding and research. PanGenomes describe the available genetic diversity within\, for instance\, plant species\, crops or germplasm collections. Because of diminishing costs of genome sequencing\, increasing speed of reference genomes construction and advances in bioinformatics\, PanGenomes have become an accessible tool. The genome insights delivered by PanGenomes can spectacularly speed up and contribute to plant breeding and research.
URL:https://www.europabio.org/event/keygenes-two-part-webinar-on-pangenomes-needs-value-and-applications-part-2/
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-KeyGene2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210318T110000
DTEND;TZID=Europe/Brussels:20210318T154500
DTSTAMP:20260527T145125
CREATED:20210128T095510Z
LAST-MODIFIED:20210212T162859Z
UID:903-1616065200-1616082300@www.europabio.org
SUMMARY:#EUIndustryWeek2021: BIO NRW
DESCRIPTION:Driving Change – How Green Chemistry and Digitalisation lead the way to a Sustainable EconomyThe focus of their event is green chemistry and sustainable processes\, focusing on how biotechnology and digitalization can contribute to the green transition. Watch the intervention from EuropaBio on on the EU perspective and what the industry suggests to drive innovation forward on the first day.
URL:https://www.europabio.org/event/bio-nrw-eu-industry-week/
CATEGORIES:External,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-BIO-NRW.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210317T140000
DTEND;TZID=Europe/Brussels:20210317T160000
DTSTAMP:20260527T145125
CREATED:20210209T171912Z
LAST-MODIFIED:20210308T094239Z
UID:1296-1615989600-1615996800@www.europabio.org
SUMMARY:Empowering the Circular Bioeconomy through the EU Green Deal
DESCRIPTION:The 2020 Circular Economy Action Plan is one of the main blocks of the European Green Deal – Europe’s new agenda for sustainable growth – including initiatives along the entire life cycle of products and aiming at rendering sustainable products the norm in the EU. It focuses on boosting circular economy processes\, fostering sustainable consumption\, and safeguarding that the resources used are kept in the economy for as long as possible. In addition\, it remains committed to making circularity work for people\, regions\, and cities\, while leading global efforts on circular economy. \n\n\n\nAt the same time\, and closely linked with the above\, the bioeconomy offers great potential in contributing to tackle environmental and societal challenges\, such as resource efficiency\, climate change\, maintaining European competitiveness and job creation. The bioeconomy can therefore play a significant role in the EU Green Deal and particularly in the transition to a circular economy\, as outlined in a position paper developed by the European Bioeconomy Alliance. As a result\, this webinar aspires to address the above developments by providing an opportunity for discussion of how to best empower the circular bioeconomy through an enabling policy framework. \n\n\n\n\n\n\n\nEvent hosted by MEP Franc Bogovič\, Chair of the Bioeconomy Working Group of the European Parliament Intergroup on ‘Climate Change\, Biodiversity and Sustainable Development’. \n\n\n\n\n\n\n\nVIRTUAL EVENT
URL:https://www.europabio.org/event/empowering-the-circular-bioeconomy-through-the-eu-green-deal/
LOCATION:VIRTUAL\, Rue de la Science 10\, Brussels\, 1000\, Belgium
CATEGORIES:External,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-EUBA-Intergroup.png
ORGANIZER;CN="European Bioeconomy Alliance & EP Intergroup on CCBSD":MAILTO:ebcd.info@ebcd.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210310T140000
DTEND;TZID=Europe/Brussels:20210310T140000
DTSTAMP:20260527T145125
CREATED:20210308T092407Z
LAST-MODIFIED:20210308T093731Z
UID:1541-1615384800-1615384800@www.europabio.org
SUMMARY:All About RC(I) – Discussing the Renewable Carbon Strategy and Initiative
DESCRIPTION:Discuss the concept of renewable carbon and get answers to all your questions. Get to know the people and companies behind the Renewable Carbon Initiative and learn why your company should join. RCI members Cosun and UPM and nova-Institute will discuss and answer your questions. \n\n\n\nAbout the organizers \n\n\n\nThe Renewable Carbon Initiative (RCI) was initiated by nova-Institute after observing the struggles of the chemical and plastics industry facing the enormous challenges in meeting the climate goals set by the European Union and the sustainability expectations held by societies around the globe. It was clear that the industry has to go beyond using renewable energy. As decarbonisation is not an option for organic chemistry\, which is entirely based on the use of carbon\, an alternative strategy was needed. \n\n\n\n\n\n\n\n\n\nVIRTUAL EVENT
URL:https://www.europabio.org/event/all-about-rci-discussing-the-renewable-carbon-strategy-and-initiative/
LOCATION:Virtual Event
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/03/Event-Banners-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210309T090000
DTEND;TZID=Europe/Brussels:20210312T170000
DTSTAMP:20260527T145125
CREATED:20210209T164320Z
LAST-MODIFIED:20210308T094328Z
UID:1289-1615280400-1615568400@www.europabio.org
SUMMARY:Immunology Virtual Partnering (Member Discount)
DESCRIPTION:Over 4% of the world’s population suffers from one or more of the over 80 autoimmune diseases identified to date. A large variety of treatment approaches have already been developed to curb the detrimental effects of autoimmune diseases\, and the market continues to flourish. In fact\, by 2025 this market is estimated to exceed a global value of $150 billion. \n\n\n\nAt Inova\, our aim is to facilitate the bridge between science and business. Inova and Biotechnology Innovation Organization (BIO)\, in partnership with Evaluate\, are organizing this Immunology Virtual Partnering Event. Through online one-to-one meetings taking place 9-12 March\, researchers\, biotechs and biopharmaceutical companies will discuss the latest research from immunology congresses\, pitch ideas and partner to prioritize the most promising research efforts. \n\n\n\nThis event will leverage Inova and Biotechnology Innovation Organization (BIO)’s biopharma industry expertise\, leading digital networking platform and years of experience organizing partnering events to connect scientific and business communities for the benefit of patients worldwide. \n\n\n\n\n\n\n\nEuropaBio Members can benefit from a 15% discount. Please liaise with Martina Cilia for further details. \n\n\n\n\n\n\n\nVIRTUAL EVENT
URL:https://www.europabio.org/event/immunology-virtual-partnering-member-discount/
LOCATION:VIRTUAL\, 89 Rue Tronchet\, Lyon\, 69006\, France
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-Immunology.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210304T140000
DTEND;TZID=Europe/Brussels:20210304T153000
DTSTAMP:20260527T145125
CREATED:20210211T123919Z
LAST-MODIFIED:20210225T120052Z
UID:1355-1614866400-1614871800@www.europabio.org
SUMMARY:Measuring the Economic Footprint of the Biotechnology Industry in Europe
DESCRIPTION:Landscape and Positions for Economic Development: Industry and policy discussions to deliver biotechnology in Europe. \n\n\n\n\n\nEuropean GDP benefitted by €38.5 bn in 2018\, in the recent study from EuropaBio ‘Measuring the Economic Footprint of the Biotechnology Industry in Europe’.  The study looked at the economic impact of the biotechnology industry within the (then) 28 European member states\, in terms of gross value added (GVA)\, employment and trade.  Including spill over effects\, that number rises to €78.7bn.  The direct contribution adds up to about 1.5% of total industrial GVA within the countries assessed\, supported by 223\,000 direct jobs rising to over 700\,000 with associated employment. \n\n\n\nVery few other sectors enhance quality of life\, knowledge\, innovation\, productivity\, andenvironmental protection as biotechnology does.  \n\n\n\nJoin EuropaBio on March 4 to find out more about the the economic footprint of biotechnology in Europe and be part of the discussion on its role in future economic recovery and delivering healthy people and planet.
URL:https://www.europabio.org/event/measuring-the-economic-footprint-of-the-biotechnology-industry-in-europe-landscape-and-positions-for-development/
CATEGORIES:EuropaBio,Healthcare Biotech,Industrial Biotech
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2021/02/WebEx-Event-Banner-WifOR.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210303T084500
DTEND;TZID=Europe/Brussels:20210303T121500
DTSTAMP:20260527T145125
CREATED:20210203T212715Z
LAST-MODIFIED:20210212T163056Z
UID:1157-1614761100-1614773700@www.europabio.org
SUMMARY:Annual Conference on EU Law in the Pharmaceutical Sector
DESCRIPTION:Annual Conference on EU Law in the Pharmaceutical Sector (3-5 March 2021) \n\n\n\nObjective \n\n\n\nThis online conference will bring legal practitioners working with the pharmaceutical sector up-to-date on the latest relevant regulatory developments\, legislative initiatives and case law. \n\n\n\nKey topics \n\n\n\nImpact of recent rulings from the CJEU on supplementary protection certificates\, patent settlements\, and online sales of medicinal products Ongoing European Commission cases on competition lawTowards a European Health Data SpaceThe European Commission’s Pharmaceutical StrategyInitiatives related to Covid-19: shortage of medicines\, dependency on raw materials from outside the EU\, cooperation between Member StatesFair competition between pharmaceutical companies in times of Covid-19 and Brexit\n\n\n\nWho should attend? \n\n\n\nIn-house counsel\, lawyers in private practice\, lawyers in national ministries and authorities dealing with regulation of the sector. \n\n\n\nInteractive online event \n\n\n\nThe conference will be hosted on ERA’s own online platform. You will be able to interact immediately and directly with our top-level speakers and other participants. We will make the most of the technical tools available to deliver an intensive\, interactive experience. As the platform is hosted on our own server\, the highest security settings will be applied to ensure that you can participate safely in this high-quality online conference. \n\n\n\n\n\n\n\nNetworking \n\n\n\nNetworking opportunities where participants can meet each other and chat with speakers will be offered. \n\n\n\nEuropaBio Members can benefit of a 25% discount on the price. Please liaise with Martina Cilia (m.cilia@europabio.org) to receive detailed information on the discount code.
URL:https://www.europabio.org/event/annual-conference-on-eu-law-in-the-pharmaceutical-sector/
LOCATION:VIRTUAL\, Metzer Allee 4\, Trier\, D-54295\, Germany
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-ERA.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210302T090000
DTEND;TZID=Europe/Brussels:20210305T170000
DTSTAMP:20260527T145125
CREATED:20210209T163156Z
LAST-MODIFIED:20210212T163115Z
UID:1278-1614675600-1614963600@www.europabio.org
SUMMARY:Oncology Virtual Partnering (Member Discount)
DESCRIPTION:Oncology is one of the most challenging areas for research and development\, but there are critical junctures where the right environment is crucial for success – and where partnering can help bring the best science forward. \n\n\n\nAt Inova\, our aim is to facilitate the bridge between science and business. Inova and Biotechnology Innovation Organization (BIO)\, in partnership with Evaluate\, are organizing this Oncology Virtual Partnering Event. Through online one-to-one meetings taking place 2 – 5 March\, researchers\, biotechs and biopharmaceutical companies will discuss the latest research from oncology congresses\, pitch ideas and partner to prioritize the most promising research efforts. \n\n\n\nThis event will leverage Inova and Biotechnology Innovation Organization (BIO)’s biopharma industry expertise\, leading digital networking platform and years of experience organizing partnering events to connect scientific and business communities for the benefit of patients worldwide. \n\n\n\n\n\n\n\nEuropaBio Members can benefit from 15% discount. Please liaise with Martina Cilia for further details.
URL:https://www.europabio.org/event/oncology-virtual-partnering-member-discount/
LOCATION:VIRTUAL\, Inova Software\, 89 Rue Tronchet\, Lyon\, 69006\, France
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-Oncology.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210301T093000
DTEND;TZID=Europe/Brussels:20210302T170000
DTSTAMP:20260527T145125
CREATED:20210203T211251Z
LAST-MODIFIED:20210212T163133Z
UID:1150-1614591000-1614704400@www.europabio.org
SUMMARY:1st International Conference on Rare Diseases
DESCRIPTION:1st International Conference on Rare Diseases \n\n\n\nDifferent infrastructures and organisational arrangements are required in each country to address the healthcare needs of its rare disease population in an effective way. Whether a single rare disease affects thousands or only a handful of individuals\, they all share similar challenges to get a timely diagnosis\, face the same barriers to access highly specialized care and treatment options and need to deal with a substantial psychosocial burden. \n\n\n\nThe health of people living with a rare disease should not be left to luck or chance especially amidst the COVID-19 pandemic. Planning ahead requires all stakeholders to acknowledge their individual responsibility to build a successful pathway from diagnosis to access and at the same time\, commit to work together in a much more agile and coordinated way than what we have seen so far. If we fail to do so\, we will have failed the 30 million people living with a rare disease in Europe. \n\n\n\nThe 1st International Conference on Rare Diseases “Building a Pathway from Diagnosis to Access” recognises that the next decade holds great potential for improvement and that while we cannot predict the future\, we all have a role in preparing for it. As the EU shapes its future regulations\, strategies and access policies\, this conference will serve as an opportunity to press the ‘pause button’ and take the time to co-create policy options today that can lead to a better patient journey in the future. \n\n\n\nEngaging all stakeholders to take action\, the 1st International Conference on Rare Diseases aspires to bring together all stakeholders in the rare disease community – patient representatives\, policy makers\, clinicians\, researchers\, industry representatives\, payers and regulators to exchange invaluable knowledge with the aim to enhance dialogue and promote policy changes to help build a better pathway from Diagnosis to Access for Rare Diseases.
URL:https://www.europabio.org/event/1st-international-conference-on-rare-diseases/
LOCATION:VIRTUAL\, 338. Kleisthenous Str.\, Gerakas\, Attiki\, 15344\, Greece
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-Rare-Diseases.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210223T110000
DTEND;TZID=Europe/Brussels:20210223T123000
DTSTAMP:20260527T145125
CREATED:20210203T204218Z
LAST-MODIFIED:20210225T111812Z
UID:1135-1614078000-1614083400@www.europabio.org
SUMMARY:#EUIndustryWeek2021: The next Industrial Revolution is a Bio Revolution
DESCRIPTION:Global challenges like COVID-19 and climate change require a range of solutions\, including those coming from innovative biotechnology. Life sciences and biotechnology is a key industrial sector which can play a transformative role in securing the EU’s competitive edge in health and sustainability.From new treatments for rare diseases to bio-based products\, biotechnology can revolutionize our approach to global challenges\, paving the way for an industrial revolution driven by the life sciences. \n\n\n\nJoin EuropaBio for presentations and discussion around the key issues where biotechnology is making a difference and how the scientific and business landscape will enable it in the future.Our panel will discuss the innovation potential of industrial and healthcare biotechnology for long term and future EU competitiveness\, including biotech SMEs as a critical part of the EU life sciences ecosystem\, and the need for a strategic approach for investment and innovation.Confirmed speakers: \n\n\n\nDr Marcus Remmers\, CTO\, Royal DSMMr Geoffrey Pot\, VP operations\, Takeda & bio.be ChairmanProf Isabel Rocha\, Pro-Rector of Nova University of LisbonDr Armin Spök\, TU Graz\, CHIC H2020 Project\n\n\n\nThis webinar is hosted by EuropaBio under the umbrella of the EU Industry Days and will be moderated by Dr Claire Skentelbery (Director-General\, EuropaBio).You can download below the speakers’ presentations: \n\n\n\nEU-Industry-Days-EuropaBio-Event-Armin-Spoek-PresentationDownload\n\n\n\nEU-Industry-Days-EuropaBio-Event-Geoffrey-Pot-PresentationDownload\n\n\n\nEU-Industry-Days-EuropaBio-Event-Isabel-Rocha-PresentationDownload\n\n\n\nEU-Industry-Days-EuropaBio-Event-Marcus-Remmers-PresentationDownload
URL:https://www.europabio.org/event/euindustryweek2021-the-next-industrial-revolution-is-a-bio-revolution/
LOCATION:VIRTUAL\, Avenue des Arts 53\, Brussels\, 1000\, Belgium
CATEGORIES:EuropaBio,Healthcare Biotech,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-EU-Ind.-Week-Ebio.png
END:VEVENT
END:VCALENDAR